MRUS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 114746 min ago

@ $42.61

Wydano: 14 vas. 2024 @ 21:47

Zwrot: 13.49%

Poprzedni sygnał: vas. 13 - 22:34

Poprzedni sygnał: Sprzedaż

Zwrot: 1.44 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	286 201
Średni wolumen	637 417
Kapitalizacja rynkowa	2.80B
EPS	$-1.040 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.12
ATR14	$0.0570 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-19	Shuman Harry	Sell	115	Common Shares
2023-12-15	Silverman Peter B.	Buy	1 286	Common Shares
2023-12-15	Silverman Peter B.	Buy	21 100	Common Shares
2023-12-15	Silverman Peter B.	Sell	21 100	Share Option (right to buy)
2023-12-15	Silverman Peter B.	Sell	22 386	Common Shares

INSIDER POWER
69.18
Last 99 transactions
Buy: 2 523 001 \| Sell: 3 636 553

Wolumen Korelacja

Długi: -0.24 (neutral)

Krótki: -0.16 (neutral)

Signal:(35.527) Neutral

Merus NV Korelacja

10 Najbardziej pozytywne korelacje
HOWL	0.948
YMAB	0.946
CGEM	0.943
SLN	0.941
NVCN	0.937
REYN	0.935
KYMR	0.934
BRIVU	0.931
PPH	0.929
VERA	0.929

10 Najbardziej negatywne korelacje
WINT	-0.939
REVB	-0.937
VALN	-0.937
BIOL	-0.933
SRNGW	-0.933
VRM	-0.931
LHDX	-0.931
SGML	-0.93
TENX	-0.928
IMV	-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Merus NV Korelacja - Waluta/Towar

-0.20
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.47
( neutral )

-0.41
( neutral )

Merus NV Finanse

Annual	2023
Przychody:	$43.95M
Zysk brutto:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2023
Przychody:	$43.95M
Zysk brutto:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2022
Przychody:	$41.59M
Zysk brutto:	$29.60M (71.19 %)
EPS:	$-2.92

FY	2021
Przychody:	$49.11M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.730

Financial Reports:

No articles found.

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.